Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies

Bladder cancer represents the most common type of urothelial carcinoma, with a median overall survival of 12.5 –15 months in the case of metastatic disease. We evaluated the role of stereotactic body radiation therapy (SBRT) in the management oligometastatic urothelial cancer.

Source: Clinical Oncology - July 24, 2020 Category: Radiology Authors: C. Franzese, G. Francolini, L. Nicosia, F. Alongi, L. Livi, M. Scorsetti Tags: Original Article Source Type: research